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Abstract
Background: Statins have anti-inflammatory and immunomodulatory properties in addition to lipid-lowering effects.
Objectives: To report the 12-month extension of a phase II trial evaluating the efficacy, safety and tolerability of atorvastatin
40 mg/d added to interferon beta-1b (IFNB-1b) in relapsing-remitting multiple sclerosis (RRMS).
Methods: In the randomized, multicenter, parallel-group, rater-blinded core study, 77 RRMS patients started IFNB-1b. At
month three they were randomized 1:1 to receive atorvastatin 40 mg/d or not in addition to IFNB-1b until month 15. In the
subsequent extension study, patients continued with unchanged medication for another 12 months. Data at study end
were compared to data at month three of the core study.
Results: 27 of 72 patients that finished the core study entered the extension study. 45 patients were lost mainly due to a
safety analysis during the core study including a recruitment stop for the extension study. The primary end point, the
proportion of patients with new lesions on T2-weighted images was equal in both groups (odds ratio 1.926; 95% CI 0.265–
14.0007; p = 0.51). All secondary endpoints including number of new lesions and total lesion volume on T2-weighted
images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC,
relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either. The
combination therapy was well tolerated.
Conclusions: Atorvastatin 40 mg/day in addition to IFNB-1b did not have any beneficial effects on RRMS compared to IFNB-
1b monotherapy over a period of 24 months.
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Introduction
Statins have anti-inflammatory and immunomodulatory prop-
erties in addition to its cholesterol-lowering effects [1]. Various
experimental studies suggest a positive effect of statins on multiple
sclerosis (MS), a chronic inflammatory disorder of the central
nervous system [2–6].
We therefore performed the SWiss Atorvastatin and Interferon
Beta-1b trial in Multiple Sclerosis (SWABIMS), a multi-centre,
randomized, parallel-group, rater-blinded study that evaluated the
efficacy, safety and tolerability of atorvastatin 40 mg per os daily
and subcutaneous interferon beta-1b (IFNB-1b) every other day
compared to monotherapy with subcutaneous IFNB-1b every
other day on relapsing-remitting MS (RRMS) over a period of 12
months [7,8]. SWABIMS did not show any beneficial effect of
atorvastatin added to IFNB-1b which is in line with other
combination trials of statins and IFNB in RRMS (Table 1) [9–15].
Herein, we present the results of the preplanned extension of
SWABIMS for another 12-months with unchanged medication
that was designed to test the effect of atorvastatin 40 mg in
addition to IFNB-1b compared to IFNB-1b monotherapy over a
period of 24 months (SWABIMS Extension Study).
Materials and Methods
Patients
In the core study, patients with RRMS according to the 2005
McDonald’s criteria, disease duration.three months, at least one
relapse in the past two years, $ three lesions on spinal or brain-
MR or both, baseline Expanded Disability Status Scale (EDSS)
score from 0 to 3.5 (inclusive), and age from 18 to 55 years were
eligible to participate [16,17]. Main exclusion criteria were
primary or secondary progressive MS, clinically isolated syn-
drome, previous therapy with monoclonal antibodies, mitoxan-
trone, other cytotoxic or immunosuppressive drugs, and IFNB or
glatiramer acetate within the last 12 months. All patients who
completed the core study were eligible to enter the extension study.
Ethics Statement
Each patient had to provide a separate written informed
consents prior to the extension study and the study was conducted
in accordance with the International Conference on Harmonisa-
tion Guidelines for Good Clinical Practice (1996) and the
Declaration of Helsinki (2006), and approved by the responsible
cantonal ethics committees of the participating centers (Cantonal
ethics committee Bern: University hospital Bern, Spitalzentrum
Biel; Cantonal ethics committee Aarau: Cantonal Hospital Aarau;
Cantonal ethics committee Luzern: Cantonal Hospital Lucerne;
Cantonal ethics committee Thurgau: Cantonal Hospital Muen-
sterlingen; Cantonal ethics committee Basel: University Hospital
Basel) and the ‘‘Swiss agency for the authorisation and supervision
of therapeutic products’’ (Swissmedic) [18,19]. The trial Registra-
tion Identifier for the SWABIMS Extension Study is
NCT01111656 (clinicaltrials.gov). The trial Registration Identifier
of the core study (SWABIMS) is NCT00942591 (clinicaltrials.gov).
Study Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The core study was a multi-centre, randomized,
parallel-group, rater-blinded study conducted in eight Swiss
hospitals [7,8]. At the beginning of the study, all patients started
IFNB-1b (BetaferonH/BetaseronH, Bayer Schering Pharma) for
three months [20]. At month three, they were randomized 1:1 to
receive atorvastatin 40 mg/day or not in addition to IFNB-1b for
another 12 months.
Randomization was performed centrally by the clinical research
organisation (CRO) after baseline visit in four-block size,
according to the randomization list (atorvastatin ‘‘yes’’ or ‘‘no’’)
Table 1. Overview of published clinical studies evaluating the combination of statins and IFNB in RRMS.
Study type Patients Allocation IFNB Statin Primary endpoint/Results
Paul F et al.
2008 [9]
open-label baseline-
to treatment trial
RRMS (n = 41) IFNB+statin (n = 16);
Statin (n = 25)
IFNB-1a 22 mg t.i.w.
or IFNB-1b e.o.d.
atorvastatin
80 mg/d
Trend towards reduction of Gd-
enhancing lesions with
IFNB+atorvastatin (p = 0.060)
Birnbaum G et al.
2008 [11]
double-blind,
placebo controlled
trial
RRMS (n = 26) IFNB+placebo (n = 9);
IFNB+statin (n = 17)
IFNB-1a 44 mg t.i.w. atorvastatin 80
mg/d (n = 10) or
40 mg (n = 7)
Increased MRI and clinical disease
activity with atorvastatin (p = 0.019)
Rudick RA et al.
2009 [12]
post hoc analysis RRMS (n = 582) IFNB (n = 542);
IFNB+statin (n = 40)
IFNB-1a 30 mg once
weekly
atrovastatin or
simvastatin
No difference in annualized relapse rate
and secondary endpoints
Lanzillo R et al.
2010 [13]
Longitudinal
controlled trial
RRMS (n = 45) IFNB (n = 24);
IFNB+statin (n = 21)
IFNB-1a 44 mg
s.c. t.i.w.
atorvastatin
20 mg/d
Fewer Gd2 enhancing lesions versus
baseline (p = 0.007) and fewer relapses
versus the two pre randomization years
(p,0.001) with atorvastatin
Togha M et al.
2010 [10]
double-blind
randomized
controlled trial
RRMS (n = 80) IFNB+placebo (n = 38);
IFNB+simvastatin
(n = 42)
IFNB-1a 30 mg
once weekly
simvastatin
40 mg/d
Lower relapse rate with simvastatin
(p = 0.01)
So¨rensen PS et al.
2011 [14]
placebo-controlled
randomised trial
RRMS (n = 307) IFNB+statin (n = 151);
IFNB+placebo
(n = 156)
IFNB-1a 30 mg
once weekly
simvastatin
80 mg/d
No difference in annualized relapse rate
and secondary endpoints
SWABIMS [8] randomized
controlled trial
RRMS (n = 76) IFNB+statin (n = 38);
IFNB (n = 38)
IFNB-1b e.o.d. atorvastatin
40 mg/d
No difference of patients with new T2-
lesions and in secondary endpoints
SWABIMS
Extension
Study
randomized
controlled trial
RRMS (n = 27) IFNB+statin (n = 13);
IFNB (n = 14)
IFNB-1b e.o.d. atorvastatin
40 mg/d
No difference of patients with new T2-
lesions and in secondary endpoints
n, number; IFNB, interferon beta; t.i.w., three times per week; d, day; e.o.d., every other day.
doi:10.1371/journal.pone.0086663.t001
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generated with ‘‘RANCODE Professional 3.60 [21]. In the
extension study, patients continued with unchanged medication
for another 12 months. The last visit of the core study was the
baseline visit of the extension study ( =month 15).
In both studies, patients and treating physicians were aware,
whether atorvastatin was added. Placebo was not dispensed.
Examining physicians scoring disability (EDSS; Multiple Sclerosis
Functional Composite [MSFC]) and neuroradiologists evaluating
magnetic resonance images (MR) were blinded to treatment
assignments [22].
Study Endpoints
The study endpoints of the core and the extension study were
identical. Data at the end of the extension study were primarily
compared to data at month three of the core study, before
randomization to atorvastatin or not.
The primary endpoint was the proportion of patients with new
lesions on T2-weighted MR images. Secondary endpoints were the
number of new lesions on T2-weighted images, change in total
lesion volume on T2-weighted images (burden of disease), total
number of gadolinium (Gd2) enhancing lesions on T1-weighted
images, changes in volume of grey and white matter, clinical
disease progression (EDSS, MSFC), relapse rate, time to first
relapse, number of relapse-free patients, and neutralizing anti-
bodies (NAbs).
Adverse events (AE), laboratory data, vital signs and concom-
itant medication were analyzed as safety variables.
Study Procedures
Regular visits were conducted at baseline, month six and month
12 during the extension study. Safety assessments including
laboratory analysis and evaluation of concomitant medication
were performed on each visit. At baseline and month 12, the
EDSS, MSFC, neutralizing antibodies (NAbs), brain MRI, as well
as other efficacy and safety endpoints were aditionally performed.
Furthermore, patients were called at month three and nine for the
assessment of safety issues and concomitant medication.
Atorvastatin use was controlled by counting the returned tablets
at month 6 and 12. A patient was considered compliant when he
took at least 80% of all atorvastatin tablets.
A relapse was defined as a newly appearing objective
neurological abnormality in the absence of fever or known
infection, correlating with the patient’s reported symptoms, lasting
for at least 24 hours, occuring at least 30 days after a preceding
clinical event, and increasing the total EDSS score or at least one
of the functional systems of the EDSS score. Fatigue, mental and/
or vegetative symptoms were not classified as relapse. Relapses
were treated within seven days with intravenous methylprednis-
olone 500 mg/day for five days followed by tapering-out with oral
prednisolone.
Atorvastatin was reduced to 20 mg/d in case of a more than
threefold increase of transaminases and stopped in case of more
than fivefold increase. Afterwards, liver enzymes were controlled
regularly and atorvastatin was continued when transaminases were
below a threefold increase.
MR scans were acquired at each hospital on 1.5 Tesla scanners
at baseline and month 12. The MR protocol included T1-
weighted axial spin-echo, T1-weighted sagittal 3D MPRAGE,
axial dual-echo i.e. proton-density, T2-weighted turbo-spin-echo
images and axial T1-weighted spin-echo images after intravenous
Gd-injection.
MR scans were assessed centrally by two neuroradiologists at
the Department of Diagnostic and Interventional Neuroradiology,
Inselspital, University Hospital Bern [23,24]. A T2 lesion was
defined as an area of increased signal on both the proton-density
and the T2-weighted images. Disagreeing interpretations were
discussed among the neuroradiologists to reach consensus. The
image processing was performed with an algorithm enabling semi-
automatic volumetry [25].
Laboratory analyses except NAbs were performed by Viollier
AG (4002 Basel, Switzerland). NAbs were assessed at the Ospedale
San Luigi, Orbassano, Italy. The cytopathic effect assay was used
as recommended by the World Health Organization [26]. Data
from the neutralisation assay were reported as reciprocal of the
highest dilution of serum inducing 50% neutralisation. The
neutralisation titre was calculated according to Kawade’s formula
and expressed in laboratory units (LU). A concentration of .20
LU/ml was considered positive [27]. Patients with one or more
NAb positive titers were defined NAb positive.
Statistical Analysis
SAS version 9.2 was used for all statistical analyses. For the core
study with regard to the first treatment year, a sample size of 38
patients in each group was needed to obtain a power of 84% to
detect the difference between the monotherapy group proportion,
p1, of 0.610 and the combination therapy group proportion, p2, of
0.910 with a 0.05 two-sided significance level in the Fisher’s exact
test [8]. All patients, who took at least one dose of study medication
and had at least one follow-up observation were analyzed (Full
Analysis Set [FAS]). Missing values were treated as missing, exept
for severity and relationship of adverse events to study drugs. If
severity or relationship was missing, the adverse event was regarded
as severe or related to the study drug respectively.
Categorical data were described by frequency and percentage,
continuous data by mean, standard deviation, minimum, 1st
quartile, median, 3rd quartile and maximum. Hypothesis tests
were carried out with a a-level of 0.05, two-sided. All inferential
analyses were presented by p-values, point estimations and two-
sided 95% CI for treatment differences. If the assumption of
normality in the linear models was not fulfilled, transformations of
the data or non-parametric approaches like the Wilcoxon signed
rank test were used.
Differences between treatment groups at baseline were tested using
t-test or Fisher’s exact test depending on the distribution of the data.
The primary efficacy variable was the proportion of patients
with new T2 lesions at month 12 of the SWABIMS Extension Study
compared to month three of SWABIMS, i.e. new T2 lesions
emerging over a period of 24 months with active treatment. Based
on a logistic regression model with the factors treatment and gender
and the covariates number of T2 lesions, number of Gd-enhancing
lesions, EDSS, relapse rate and time since MS diagnosis at baseline
at month three, the two-sided hypothesis of equality between the
two treatments was tested at an a-level of 0.05. The results were
presented as odds ratios and the associated two-sided 95%CI and p-
values. Furthermore, a Fisher’s exact test for proportions was
executed to test for the unadjusted treatment effect.
Secondary efficacy variables were analyzed with covariance,
logistic regression models or Fisher’s exact test depending on the
distribution. Time to first relapse was analyzed with non-
parametric methods for failure time data (Wilcoxon test).
Assessments of safety and tolerability variables were presented
by treatment group. AEs were summarized for each treatment
group by presenting the number and percentage of subjects having
an event, the number and percentage of event in each system
organ class and preferred term, as well as severity and relationship
to the study drug.
Any medication taken during the study was classified as
concomitant and coded using WHO-Drug 2007.1.
Atorvastatin and Interferon in Multiple Sclerosis
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Results
From August 2006 to March 2009, 27 out of 72 patients who
finished the core study entered the extension study. 45 patients
were lost mainly due to a safety analysis during the core study
including a recruitment stop for the extension study imposed by
the local institutional review board (IRB), because a study of
Birnbaum et al. suggested a negative effect of statins in combina-
Figure 1. CONSORT Flow diagram showing enrollment, allocation and follow-up of patients in the SWABIMS and SWABIMS
Extension Study.
doi:10.1371/journal.pone.0086663.g001
Atorvastatin and Interferon in Multiple Sclerosis
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Table 2. Patient characteristics at screening/baseline of month three of SWABIMS.
Characteristics
Atorvastatin/Interferon
beta-1b Interferon beta-1b P Value
N=13 N=14
Demographic characteristics at screening/baseline
Age (years)
Mean 6 SD 32.1569.61 36.9368.24 0.17
Median (range) 30 (19–50) 39 (18–46)
Gender (N, %)
Male 3 (23.1%) 5 (35.7%)
Female 10 (76.9%) 9 (64.3%) 0.68
Caucasian (N, %) 13 (100%) 14 (100%)
Height (cm)
Mean 6 SD 171.0867.61 170.71610.63
Median (range) 170 (156–188) 168 (157–187) 0.77
Weight (kg)
Mean 6 SD 69.19611.29 77.46622.06
Median (range) 68 (54.6–100) 73.5 (52–124) 0.47
BMI (kg/m2)
Mean 6 SD 23.8264.62 26.4567.01
Median (range) 24.68 (18.14–34.6) 24.45 (20.06–45.55) 0.51
MR findings at month 3 of SWABIMS
No. of T2 hyperintense lesions
N 12 14
Mean 6 SD 26.17623.03 19.86616.38
Median (range) 21.5 (6–92) 13.5 (2–58) 0.46
Total volume of T2 hyperintense lesions [cm3]
N 12 14
Mean 6 SD 3.663.31 2.9362.98
Median (range) 2.96 (0.36–12.35) 1.78 (0.15–8.98) 0.40
No. of GD-enhancing lesions on T1-weighted images
N 13 14
Mean 6 SD 0.2360.6 0.060.0
Median (range) 0 (0–2) 0 (0–0) 0.15
Total volume of GD-enhancing lesions on T1-weighted images [cm3]
N 13 14
Mean 6 SD 0.0360.08 060
Median (range) 0 (0–0.3) 0 (0–0) 0.15
Volume of grey matter [cm3]
N 9 13
Mean 6 SD 728.11674.4 736.65684.99
Median (range) 729.4 (620–867) 732.3 (614–880) 0.95
Volume of white matter [cm3]
N 9 13
Mean 6 SD 432.73641.58 435.55678.13
Median (range) 423.5 (386–494) 450.9 (270–544) 0.95
Volume of grey and white matter [cm3]
N 9 13
Mean 6 SD 1160.86684.61 1172.206127.43
Median (range) 1163.0 (1070–1336) 1149.8 (991–1379) 0.89
Clinical characteristics
MS duration at screening (years)
Atorvastatin and Interferon in Multiple Sclerosis
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tion with IFNB in MS [11]. Furthermore, two of the eight centres
of the core study did not participate in the extension study. The
IRB decision was revised after a safety analysis performed by B.
Weinshenker and M. Matiello (Rochester MN, USA) showed no
reason to terminate the trials which led to a continuation of the
study. 14 patients were in the IFNB-1b group and 13 patients in
the atorvastatin/IFNB-1b group. All 27 patients completed the
extension study (Figure 1). Because of the unintended small patient
number we performed a new power analysis that showed that a
sample size of 13 in each group is needed to obtain power of 81%
to detect differences between the atorvastatin/IFNB-1b group
proportion, p1, of 0,923 and the IFNB-1b group proportion, p2,
of 0,373 with a 0,050 two-sided significance level in the Fisher’s
exact test with regard to the overall treatment duration of 24
month [8].
The atorvastatin compliance was .80% during the study and
all relapses were treated with steroids as defined above.
The baseline demographic charateristics and the disease
characteristics at month three of the core study, before
randomisation to atorvastatin or not, showed no significant
differences regarding the treatment groups (Table 2).
The results for the primary and secondary efficacy endpoints
are given in Table 3.
The proportion of patients with new lesions on T2-weighted
images showed no differences according to the logistic regression
model (p = 0.51). The adjusted odds ratio (OR) and the 95% CI
for the treatment difference of atorvastatin/IFNB-1b vs. IFNB-1b
were 1.926 and 0.265 to 14.0007. To test the unadjusted
treatment differences, an exploratory analysis with Fisher’s exact
test was performed. Again, no significant difference was detected
(p = 0.45).
The predefined secondary endpoints number of new lesions and
total lesion volume on T2-weighted images, total number of Gd-
enhancing lesions on T1-weighted images, volume of grey and
white matter, EDSS, MSFC (including subscores), relapse rate,
number of relapse-free patients and NAb did not show any
significant differences between the treatment groups as well. The
secondary endpoint time to next relapse was not calculated due to
a low number of events.
Some data on MR endpoints were missing due to movement
artefacts during single MR sequences. Furthermore, two centers
did not provide adequate MRI data for grey and white matter
analysis and did not collect NAbs explaining the lower numbers of
individuals in these endpoints.
There was a trend towards a higher number of new lesions on
T2-weighted images and total number of Gd-enhancing lesions on
T1-weighted images in the atorvastatin/IFNB-1b group.
An ANCOVA model with new lesions on T2-weighted images
respectively the total number of Gd-enhancing lesions on T1-
weighted images as dependent variables and new lesions on T2-
weighted images, total number of Gd-enhancing lesions on T1-
weighted images, EDSS, relapse rate, gender, disease duration and
treatment as independent variables showed that the number of
Gd-enhancing lesions at baseline respectively gender had a
relevant influence on these enpoints whereas treatment did not.
Details on AEs by system organ class are given in Table 4.
During the extension study any AEs including serious and severe
AEs occurred equally in both groups. There was no discontinu-
ation of the study drug due to AEs. Two AEs, an influenza-like
illness and increased hepatic enzymes were judged as related to the
study drug in the atorvastatin/IFNB-1b group. Elevated liver
enzymes occurred in two patients of the atorvastatin/IFNB-1b
group without clinical relevance. In the atorvastatin/IFNB-1b
Table 2. Cont.
Characteristics
Atorvastatin/Interferon
beta-1b Interferon beta-1b P Value
N=13 N=14
N 13 14
Mean 6 SD 1.4564.51 1.2162.2 0.45
No. of relapses in the past 2 years before screening (N, %)
N 13 14
1 6 (46.2%) 5 (35.7%)
2 7 (53.8%) 9 (64.3%)
3 0 (0%) 0 (0%)
4 0 (0%) 0 (0%)
8 0 (0%) 0 (0%) 0.70
EDSS at month 3
N 13 14
Mean 6 SD 1.8860.79 1.7560.91
Median (range) 2 (1–3.5) 2 (0–3) 0.96
MSFC at month 3
N 13 14
Mean 6 SD 0.4260.26 0.2460.39
Median (range) 0.41 (20.05–0.8) 0.37 (20.37–0.73) 0.32
N: number of patients; SD: standard deviation; EDSS: Expanded Disability Status Scale; MSFC: Multiple Sclerosis Functional Composite; BMI: body mass index; ns: no
significant difference.
doi:10.1371/journal.pone.0086663.t002
Atorvastatin and Interferon in Multiple Sclerosis
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Table 3. Efficacy endpoints: Month 3 of SWABIMS compared to the end of SWABIMS Extension Study (month 27) (FAS, N = 27).
Endpoint Atorvastatin/Interferon-beta-1b Interferon-beta-1b P Value
N=13 N=14
MR endpoints
Proportion of patients with new lesions on T2-weighted images, month 3 to month 27 (N; %)
N 12 14
Yes 8 (66.67) 7 (50.00)
No 4 (30.33) 7 (50.00)
Odds ratio for atorvastatin/IFNB-1b vs. IFNB-1b (95% CI) 1.926 (0.265 to 14.007) 0.51
No. of new lesions on T2-weighted images, month 3 to month 27
N 12 14
Mean 6 SD 5.066.59 1.461.82
Median (range) 1 (0–16) 0.5 (0–5)
Treatment difference for atorvastatin/IFNB-1b vs. IFNB-1b (95% CI)" 3.64 (20.37 to 7.65) 0.07
Change in lesion volume [cm3] on T2-weighted images, month 3 to month 27
N 12 13
Mean 6 SD 20.061.51 20.661.17
Median (range) 0.3 (23–3) 20.4 (23–0)
Treatment difference for atorvastatin/IFNB-1b vs. IFNB-1b (95% CI)" 0.55 (20.35 to 1.44) 0.22
Total number of Gd-enhancing T1-lesions, month 3 to month 27
N 13 14
Mean 6 SD 20.160.76 0.060.00
Median 0 (2221) 0 (020)
Treatment difference for atorvastatin/IFNB-1b vs. IFNB-1b (95% CI)" 0.22 (20.03 to 0.48) 0.08
Change of grey matter volume [cm3], month 3 to month 27
N 8 11
Mean 6 SD 3.9635.85 218.3661.23
Median (range) 27.7 (238–73) 25.2 (2190–45) 0.72
Change of white matter volume [cm3], baseline at month 3 to month 27
N 8 11
Mean 6 SD 20.8618.34 8.6642.02
Median (range) 0.7 (231–30) 21.7 (242–118) 0.81
Change of grey and white matter volume [cm3], month 3 to month 27
N 8 11
Mean 6 SD 3.1630.22 29.7642.09
Median (range) 20.3 (238–47) 211.7 (279–67) 0.82
Clinical endpoints
Change in EDSS score, month 3 to month 27
N 13 14
Mean 6 SD 0.15461.2142 20.03661.1174
Median (range) 0 (22–3.50) 0 (22–2)
Least squares means for effect treatment (95% CI)" 0.66 (20.25 to 1.56) 0.14
Change in MSFC score, month 3 to month 27
N 13 14
Mean 6 SD 20.360.62 20.460.53
Median (range) 20.2 (21–1) 20.2 (22–0)
Least squares means for effect treatment (95% CI)" 0.07 (20.41 to 0.56) 0.74
Relapses, month 3 to month 27
N 13 14
Relapse-free (N, %)
No 7 (53.85) 4 (28.57)
Yes 6 (46.15) 10 (71.43)
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group, all AEs were classified as mild or moderate. There was no
severe or serious AE. In the IFNB-1b group, AEs were classified as
mild or moderate except for one patients with a foot fracture that
was classified as a severe as well as serious AE.
Discussion
Atorvastatin 40 mg added to IFNB-1b did not have any
beneficial effect on RRMS compared to IFNB-1b monotherapy
over a period of 24 months. There were no significant differences
in the primary or secondary endpoints between the two treatment
groups. Non-siginificant trends were due to baseline differences
and not treatment. The combination of atorvastatin and IFNB-1b
was well tolerated and did not cause unexpected or severe side
effects. All AEs were similar in both groups. Especially clinical
relevant elevated liver enzymes did not occur more frequently in
the atorvastatin/IFNB-1b group and unlike in the core study no
dose adaptation of atorvastatin was necessary [8].
The results of the SWABIMS and SWABIMS Extension study
are in line with several other combination trials of statins and
IFNB in RRMS (Table 1) [8–15]. In this regard, there is actually
no evidence to support the use of either atorvastatin or simvastatin
as an adjunctive therapy to IFNB in RRMS [28,29]. Adding
atorvastatin or simvastatin to IFNB resulted to be safe and well
tolerated without the occurance of serious side effects [28,29].
In addition, SWABIMS and the SWABIMS extension study do
not indicate a harmful effect of atorvastatin in addition to IFNB-1b
on the course of RRMS as well. This, however, is still controversial
due to individual data suggesting it [11,14,30,31].
The safe and well tolerated use of statins in combination with
IFNB in MS patients is of importance because MS patients with
vascular risk factors and vascular disease have a more rapid
disability progression than MS patients without [32,33]. SWA-
BIMS and the SWABIMS Extension Study in conjunction with
other studies suggest that atorvastatin and simvastatin can be used
for prevention of vascular events in MS patients who need a lipid-
lowering therapy.
These conclusions on atorvastatin and simvastatin are likely to
apply for other statins as well given the comparable immuno-
modulatory properties of the different statins in experimental
studies [6,34]. However, this has to be proven in separate clinical
studies.
In contrast to the negative clinical studies, statins and IFNB
have additive anti-inflammatory and immunomodulatory effects
in vitro [34]. A possible explanation for this contradiction could be
antagonistic effects of both drugs. Statins inhibit the STAT1
phosphorylation which is an important signaling pathway for
IFNB, antagonize the inhibitory effect of IFNB on the proteolytic
activity on MMP-2 and MMP-9, and reduce IFNB function and
type 1 interferon responses in RRMS patients [34–37].
However, the question whether statins alone or in combination
with other MS therapeutics could be beneficial in MS has not been
studied and has yet to be answered. Statins have anti-inflamma-
tory and immunomodulatory effects in experimetal studies
including studies in ‘‘Experimental allergic encephalomyelitis’’
(EAE), the animal model of MS [3–6,34]. Furthermore, an open-
label, single-arm study evaluating simvastatin 80 mg/d in 30
RRMS patients showed a significant decrease in the number and
volume of Gd-enhancing lesions [38]. A recent randomized,
double-blind, placebo-controlled phase II trial, that is not
published yet, showed a benificial effect of simvastatin 80 mg/d
over two years in 140 secondary-progressive MS patients on
disease progression (EDSS) and brain atrophy measures (brain
boundary shift integrals) but no effect on relapse rate or T2 lesion
Table 3. Cont.
Endpoint Atorvastatin/Interferon-beta-1b Interferon-beta-1b P Value
N=13 N=14
Odds ratio of atorvastatin/IFNB-1b vs.
IFNB-1b (95% CI) for ‘‘Patient is relapse-free’’)
0.386 (0.054 to 2.743) 0.34
No. of relapses
Total number 14 5
Mean 6 SD 1.161.44 0.460.63
Median (range) 1.0 (0–4) 0.0 (0–2) 0.23
Neutralizing antibodies (NAb)
NAb-positive (N, %)
N 11 12
No 3 (27.27) 6 (50)
Yes 8 (72.73) 6 (50)
Odds ratio of atorvastatin/IFNB-1b vs.
IFNB-1b (95% CI) for ‘‘patient is NAb-positive’’
4.10 (0.37 to 44.89) 0.25
Change from NAb-positive to NAb-negative
N 10 9
No 7 (70) 8 (88.89)
Yes 3 (30) 1 (11.11)
Odds ratio of atorvastatin/IFNB-1b vs.
IFNB-1b (95% CI) for ‘‘patient is NAb-positive’’
Cannot be calculated due to low N 0.21
N: number of patients with data; SD: standard deviation; EDSS: Expanded Disability Status Scale; MSFC: Multiple Sclerosis functional Composite; " Treatment differences
were calculated using ANCOVA.
doi:10.1371/journal.pone.0086663.t003
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activity [39]. These results indicate a possible positive effect of
statins as monotherapy in MS. The latter study additionally
emphasises a predominatly neuroprotective effect of statins in MS.
This of course needs further investigation of statins in MS alone or
in comination with other MS therapeutics.
There are limitations of the SWABIMS Extension Study. The
number of patients was low due to the mentioned loss of patients
caused by a safety analysis. Despite of the reduced statistical
power, the results of the study still give meaningful informations
with regard to the efficacy and safety of statins added to IFNB in
the treatment of MS over a period of 24 month. Furthermore, it
was not placebo-controlled because at the time of study planning
and initiation an identical placebo was not available. We therefore
chose a prospective randomized rater-blinded end-point study
design. Nevertheless, the evaluating clinicians and neuroradiolo-
gists assessing MR endpoints were blinded. Another limitation
might be the dose of atorvastatin. In vascular disease higher doses
of atorvastatin are more effective than lower doses. However, the
optimal immunomodulatory dosage is unknown and it is not
certain that higher doses yield higher efficacy. Therefore and for
safety reasons we chose a daily dose of 40 mg atorvastatin.
Conclusions
In conclusion, atorvastatin 40 mg/d in addition to IFNB-1b did
not have any beneficial effects on RRMS compared to IFNB-1b
monotherapy over a period of 24 months. There is actually no
evidence to support the use of atorvastatin 40 mg/d as an
adjunctive therapy to IFNB in RRMS. The combination therapy
was well tolerated and safe without the occurance of severe or
unexpected side effects.
Table 4. Adverse events SWABIMS Extension Study by system organ class MedDRA (FAS, N = 27).
Events N (%) Atorvastatin/Interferon-beta-1b Interferon-beta-1b
(N=13) (N=14)
Total number of adverse events 7 7
Adverse events (AE) by number of subjects
Overall adverse event 15 (53.8%) 12 (50.0%)
Subjects with
any AE 7 (53.8%) 7 (50.0%)
any serious AE 0 (0%) 1 (7.1%)
any severe AE 0 (0%) 1 (7.1%)
any AE related to study drug 2 (15.4%) 0 (0.0%)
any AE leading to discontinuation of study drug 0 (0%) 0 (0.0%)
Reported AE by number of subjects
General disorders and administration site conditions 2 (15.4%) 1 (7.1%)
Influenza like illness 1 (7.7%) 1 (7.1%)
Pyrexia 1 (7.7%) 0 (0.0%)
Infections and infestations 0 (0.0%) 1 (7.1%)
Nasopharyngitis 0 (0.0%) 1 (7.1%)
Injury, poisoning and procedural complications 0 (0.0%) 2 (14.3%)
Foot fracture 0 (0.0%) 1 (7.1%)
Joint sprain 0 (0.0%) 1 (7.1%)
Investigations 2 (15.4%) 0 (0.0%)
Hepatic enzyme increased 2 (15.4%) 0 (0.0%)
Metabolism and nutrition disorders 0 (0.0%) 1 (7.1%)
Hypercholesterolaemia 0 (0.0%) 1 (7.1%)
Musculoskeletal and connective tissue disorders 1 (7.7%) 1 (7.1%)
Arthralgia 1 (7.7%) 0 (0.0%)
Bursitis 0 (0.0%) 1 (7.1%)
Nervous system disorders 6 (46.2%) 4 (28.6%)
Headache 2 (15.4%) 0 (0.0%)
Mononeuropathy 0 (0.0%) 1 (7.1%)
Multiple slcerosis relapse 6 (46.2%) 2 (14.3%)
Tension headache 0 (0.0%) 1 (7.1%)
Vascular disorders 0 (0.0%) 1 (7.1%)
Hypertension 0 (0.0%) 1 (7.1%)
AE: adverse event; N: number.
doi:10.1371/journal.pone.0086663.t004
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